GleamWall
中文EN

TPST Tempest Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1544227 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.6%
TTM EPS YoY67.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,797.6%
ROA-313.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets120.9%
Debt / equity—
Current ratio0.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$12.61M$28.48M$17.50M$22.53M$17.17M
SG&A expense$13.97M$13.55M$11.66M$12.11M$9.82M
Operating income-$26.57M-$42.03M-$29.16M-$34.64M-$26.99M
Interest expense$207,000$1.32M$1.45M$1.62M$1.28M
Income tax$0$0$0$0$0
Net income-$26.26M-$41.84M-$29.49M-$35.71M-$28.30M
EBITDA-$26.31M-$41.64M-$28.78M-$34.00M-$26.61M
EPS (basic)-6.33-19.50-1.91-3.09-7.47
EPS (diluted)-6.33-19.50-1.91-3.09-7.47
Weighted avg. shares (diluted)4.15M2.15M15.42M11.55M3.79M
Balance sheet
Cash & equivalents$7.71M$30.71M$39.67M$31.60M$51.83M
Current assets$8.27M$31.47M$40.36M$32.95M$68.96M
PP&E, net$605,000$886,000$840,000$1.06M$1.11M
Total assets$16.93M$41.49M$51.60M$46.09M$73.24M
Current liabilities$3.31M$14.22M$9.41M$7.28M$20.03M
Short-term debt$0$6.35M$4.29M——
Long-term debt—$0$6.26M$10.37M$15.07M
Total debt—$6.35M$10.55M$10.37M$15.07M
Total liabilities$10.26M$22.36M$24.84M$27.98M$37.12M
Shareholders' equity$6.67M$19.13M$26.77M$18.11M$36.12M
Net debt—-$24.36M-$29.12M-$21.23M-$36.76M
Shares outstanding4.93M3.38M22.05M10.52M6.91M
Cash flow statement
Operating cash flow-$26.82M-$33.03M-$27.36M-$31.07M-$25.96M
Capital expenditure$0$435,000$170,000$562,000$135,000
Free cash flow-$26.82M-$33.46M-$27.53M-$31.63M-$26.09M
Investing cash flow$0-$435,000-$170,000-$562,000-$97,000
Financing cash flow$4.26M$24.50M$35.60M$11.40M$59.06M
Depreciation & amortization$266,000$389,000$381,000$638,000$374,000
Stock-based compensation$3.12M$5.30M$2.55M$1.56M$1.10M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.